TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
   PubMed Web of Science ®Google Scholar
• Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011;59:1009–1018.
   PubMed Web of Science ®Google Scholar
• Black P, So A. Perioperative chemotherapy for muscle-invasive bladder cancer. Can Urol Assoc J. 2009;3:S223–S7.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–866.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Shindo T, Itoh N. Efficacy of neoadjuvant gemcitabine and cisplatin in the management of muscle-invasive urothelial carcinoma of the bladder. Nihon Hinyokika Gakkai Zasshi. 2015;106:1–6.
   PubMedGoogle Scholar
• Chang FL, Lai MD. The relationship between p53 status and anticancer drugs-induced apoptosis in nine human bladder cancer cell lines. Anticancer Res. 2000;20:351–355.
   PubMed Web of Science ®Google Scholar
• Gore JL, Lai J, Setodji CM, et al. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a surveillance, epidemiology, and end results-medicare analysis. Cancer. 2009;115:988–996.
   PubMed Web of Science ®Google Scholar
• Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004;22:4632–4642.
   PubMed Web of Science ®Google Scholar
• Esteller M. Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol. 2005;205:172–180.
   PubMed Web of Science ®Google Scholar
• Besaratinia A, Cockburn M, Tommasi S. Alterations of DNA methylome in human bladder cancer. Epigenetics. 2013;8:1013–1022.
   PubMed Web of Science ®Google Scholar
• Kandimalla R, van Tilborg AA, Zwarthoff EC. DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol. 2013;10:327–335.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Kim WJ. Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer? Investig Clin Urol. 2016;57(Suppl 1):S77–88.
   PubMed Web of Science ®Google Scholar
• Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001;61:8659–8663.
   PubMed Web of Science ®Google Scholar
• Sathyanarayana UG, Maruyama R, Padar A, et al. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res. 2004;64:1425–1430.
   PubMed Web of Science ®Google Scholar
• Yates DR, Rehman I, Abbod MF, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res. 2007;13:2046–2053.
   PubMed Web of Science ®Google Scholar
• Urakami S, Shiina H, Enokida H, et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res off J Am Assoc Cancer Res. 2006;12:2109–2116.
   PubMed Web of Science ®Google Scholar
• Wolff EM, Chihara Y, Pan F, et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res. 2010;70:8169–8178.
   PubMed Web of Science ®Google Scholar
• Schlichtholz B, Presler M, Matuszewski M. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast. Carcinogenesis. 2004;25:2319–2323.
   PubMed Web of Science ®Google Scholar
• Uchida T, Wada C, Ishida H, et al. p53 mutations and prognosis in bladder tumors. J Urol. 1995;153:1097–1104.
   PubMed Web of Science ®Google Scholar
• Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 2005;7:363–373.
   PubMed Web of Science ®Google Scholar
• Tomasini R, Tsuchihara K, Wilhelm M, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 2008;22:2677–2691.
   PubMed Web of Science ®Google Scholar
• Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer. 2002;2:605–615.
   PubMed Web of Science ®Google Scholar
• Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 2006;13:962–972.
   PubMed Web of Science ®Google Scholar
• Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res. 2004;2:371–386.
   PubMed Web of Science ®Google Scholar
• Thanos CD, Bowie JU. p53 Family members p63 and p73 are SAM domain-containing proteins. Protein Sci. 1999;8:1708–1710.
   PubMed Web of Science ®Google Scholar
• Ciamporcero E, Shen H, Ramakrishnan S, et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. 2016;35:1541–1553.
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007;16(Spec No 1):R50–9.
   PubMed Web of Science ®Google Scholar
• Stiewe T, Zimmermann S, Frilling A, et al. Transactivation-deficient ΔTA-p73 acts as an oncogene. Cancer Res. 2002;62:3598–3602.
   PubMed Web of Science ®Google Scholar
• Ishimoto O, Kawahara C, Enjo K, et al. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 2002;62:636–641.
   PubMed Web of Science ®Google Scholar
• Rufini A, Agostini M, Grespi F, et al. p73 in Cancer. Genes Cancer. 2011;2:491–502.
   PubMedGoogle Scholar
• Grob TJ, Novak U, Maisse C, et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 2001;8:1213–1223.
   PubMed Web of Science ®Google Scholar
• Conforti F, Yang AL, Agostini M, et al. Relative expression of TAp73 and DeltaNp73 isoforms. Aging (Albany NY). 2012;4:202–205.
   PubMedGoogle Scholar
• Muller M, Schilling T, Sayan AE, et al. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ. 2005;12:1564–1577.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Hu Q, Krishnan N, et al. Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer. Cell Death Dis. 2017;8:3217.
   PubMed Web of Science ®Google Scholar